Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lenses, Intraocular | 12 | 2023 | 141 | 5.730 |
Why?
|
Corneal Diseases | 24 | 2023 | 539 | 4.910 |
Why?
|
Lens Implantation, Intraocular | 15 | 2024 | 192 | 4.390 |
Why?
|
Cornea | 31 | 2023 | 1332 | 3.890 |
Why?
|
Keratoconus | 11 | 2023 | 113 | 3.740 |
Why?
|
Fuchs' Endothelial Dystrophy | 7 | 2024 | 103 | 3.660 |
Why?
|
Corneal Transplantation | 13 | 2022 | 322 | 3.660 |
Why?
|
Descemet Stripping Endothelial Keratoplasty | 11 | 2024 | 112 | 3.520 |
Why?
|
Descemet Membrane | 7 | 2021 | 71 | 3.260 |
Why?
|
Cataract | 13 | 2024 | 837 | 3.040 |
Why?
|
Phacoemulsification | 9 | 2020 | 151 | 2.470 |
Why?
|
Visual Acuity | 34 | 2024 | 2714 | 2.430 |
Why?
|
Keratomileusis, Laser In Situ | 10 | 2014 | 84 | 2.420 |
Why?
|
Sclera | 6 | 2021 | 190 | 2.190 |
Why?
|
Corneal Edema | 5 | 2024 | 47 | 2.070 |
Why?
|
Astigmatism | 8 | 2019 | 69 | 1.910 |
Why?
|
Refraction, Ocular | 5 | 2019 | 186 | 1.900 |
Why?
|
Cataract Extraction | 10 | 2023 | 465 | 1.830 |
Why?
|
Mucopolysaccharidosis I | 4 | 2022 | 53 | 1.580 |
Why?
|
Corneal Topography | 10 | 2023 | 69 | 1.560 |
Why?
|
Erythema | 2 | 2023 | 262 | 1.550 |
Why?
|
Iris | 6 | 2023 | 231 | 1.480 |
Why?
|
Corneal Ulcer | 7 | 2023 | 127 | 1.460 |
Why?
|
Trigeminal Nerve Diseases | 2 | 2021 | 48 | 1.450 |
Why?
|
Prostheses and Implants | 9 | 2022 | 1279 | 1.400 |
Why?
|
Refractive Surgical Procedures | 3 | 2019 | 22 | 1.340 |
Why?
|
Nerve Transfer | 2 | 2021 | 133 | 1.330 |
Why?
|
Eye | 2 | 2023 | 715 | 1.290 |
Why?
|
Intraoperative Complications | 4 | 2024 | 1176 | 1.260 |
Why?
|
Artificial Organs | 4 | 2016 | 149 | 1.240 |
Why?
|
Lasers, Excimer | 6 | 2015 | 69 | 1.170 |
Why?
|
Eye Diseases | 3 | 2023 | 657 | 1.150 |
Why?
|
Anterior Eye Segment | 4 | 2012 | 144 | 1.120 |
Why?
|
Corneal Opacity | 4 | 2015 | 53 | 1.080 |
Why?
|
Myopia | 9 | 2010 | 252 | 1.040 |
Why?
|
Keratitis | 6 | 2012 | 241 | 1.040 |
Why?
|
Hyperopia | 3 | 2019 | 41 | 1.020 |
Why?
|
Eye Infections, Fungal | 5 | 2014 | 99 | 1.010 |
Why?
|
Lens Subluxation | 2 | 2016 | 23 | 0.960 |
Why?
|
Ophthalmology | 5 | 2023 | 560 | 0.920 |
Why?
|
Coloboma | 2 | 2023 | 60 | 0.900 |
Why?
|
Presbyopia | 2 | 2016 | 10 | 0.900 |
Why?
|
Eye Infections, Bacterial | 6 | 2014 | 241 | 0.900 |
Why?
|
Corneal Stroma | 6 | 2020 | 170 | 0.880 |
Why?
|
Pseudophakia | 3 | 2021 | 61 | 0.870 |
Why?
|
Corneal Wavefront Aberration | 2 | 2013 | 7 | 0.850 |
Why?
|
Aberrometry | 2 | 2013 | 8 | 0.840 |
Why?
|
Iris Diseases | 1 | 2023 | 36 | 0.840 |
Why?
|
Smallpox | 1 | 2023 | 43 | 0.830 |
Why?
|
Mucopolysaccharidoses | 2 | 2022 | 27 | 0.820 |
Why?
|
Vaccinia | 1 | 2023 | 71 | 0.820 |
Why?
|
Postoperative Complications | 15 | 2021 | 15880 | 0.810 |
Why?
|
Suture Techniques | 6 | 2021 | 776 | 0.780 |
Why?
|
Vision Disorders | 6 | 2016 | 1092 | 0.760 |
Why?
|
Eye Injuries | 5 | 2023 | 228 | 0.740 |
Why?
|
beta-Alanine | 1 | 2021 | 82 | 0.730 |
Why?
|
Contact Lenses | 2 | 2012 | 138 | 0.700 |
Why?
|
Photorefractive Keratectomy | 3 | 2008 | 38 | 0.700 |
Why?
|
Anterior Chamber | 5 | 2024 | 194 | 0.690 |
Why?
|
Endothelium, Corneal | 4 | 2020 | 215 | 0.670 |
Why?
|
Benzoates | 1 | 2021 | 213 | 0.670 |
Why?
|
Sutures | 2 | 2021 | 283 | 0.660 |
Why?
|
Eye Abnormalities | 2 | 2013 | 243 | 0.640 |
Why?
|
Prosthesis Implantation | 6 | 2016 | 595 | 0.630 |
Why?
|
Nausea | 1 | 2021 | 682 | 0.600 |
Why?
|
Aphakia, Postcataract | 1 | 2017 | 52 | 0.570 |
Why?
|
Uveal Neoplasms | 2 | 2017 | 344 | 0.560 |
Why?
|
Retinal Dystrophies | 1 | 2017 | 65 | 0.550 |
Why?
|
Tomography, Optical Coherence | 5 | 2024 | 2958 | 0.550 |
Why?
|
Ectopia Lentis | 1 | 2016 | 20 | 0.540 |
Why?
|
Prosthesis-Related Infections | 2 | 2012 | 491 | 0.540 |
Why?
|
Keratoplasty, Penetrating | 7 | 2022 | 143 | 0.540 |
Why?
|
Fluoroquinolones | 3 | 2011 | 309 | 0.520 |
Why?
|
Lens, Crystalline | 4 | 2016 | 387 | 0.500 |
Why?
|
Uveitis, Anterior | 2 | 2023 | 101 | 0.500 |
Why?
|
Lens Capsule, Crystalline | 2 | 2013 | 38 | 0.500 |
Why?
|
Eyeglasses | 1 | 2016 | 138 | 0.490 |
Why?
|
Ophthalmic Solutions | 5 | 2024 | 315 | 0.490 |
Why?
|
Iridectomy | 1 | 2015 | 48 | 0.480 |
Why?
|
Photophobia | 1 | 2015 | 77 | 0.470 |
Why?
|
Uveitis | 2 | 2023 | 398 | 0.470 |
Why?
|
Copper | 1 | 2017 | 368 | 0.460 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2019 | 712 | 0.460 |
Why?
|
Elastic Modulus | 6 | 2019 | 211 | 0.450 |
Why?
|
Humans | 117 | 2024 | 768451 | 0.450 |
Why?
|
Blindness | 2 | 2015 | 588 | 0.440 |
Why?
|
Headache | 1 | 2021 | 1260 | 0.430 |
Why?
|
Posterior Eye Segment | 1 | 2013 | 18 | 0.420 |
Why?
|
Endophthalmitis | 2 | 2014 | 262 | 0.420 |
Why?
|
Corneal Surgery, Laser | 1 | 2012 | 11 | 0.420 |
Why?
|
Optics and Photonics | 1 | 2014 | 307 | 0.410 |
Why?
|
Cosmetic Techniques | 2 | 2012 | 149 | 0.410 |
Why?
|
Coloring Agents | 1 | 2015 | 564 | 0.410 |
Why?
|
Alcaligenes | 1 | 2011 | 1 | 0.400 |
Why?
|
Glaucoma | 3 | 2022 | 1193 | 0.390 |
Why?
|
Conjunctiva | 4 | 2011 | 478 | 0.380 |
Why?
|
Accommodation, Ocular | 2 | 2016 | 47 | 0.370 |
Why?
|
Lasers, Solid-State | 2 | 2010 | 183 | 0.360 |
Why?
|
Graft Survival | 3 | 2020 | 3890 | 0.350 |
Why?
|
Aspergillosis | 1 | 2012 | 242 | 0.350 |
Why?
|
Physical Examination | 1 | 2016 | 1262 | 0.350 |
Why?
|
Keratotomy, Radial | 1 | 2009 | 3 | 0.350 |
Why?
|
Gram-Negative Bacterial Infections | 2 | 2011 | 238 | 0.350 |
Why?
|
Glaucoma, Angle-Closure | 1 | 2012 | 192 | 0.350 |
Why?
|
Anesthesia | 1 | 2021 | 1596 | 0.340 |
Why?
|
Prosthesis Fitting | 1 | 2010 | 75 | 0.330 |
Why?
|
Ocular Hypertension | 2 | 2008 | 211 | 0.330 |
Why?
|
Dry Eye Syndromes | 1 | 2014 | 388 | 0.330 |
Why?
|
Acanthamoeba Keratitis | 2 | 2007 | 14 | 0.320 |
Why?
|
Sensation Disorders | 1 | 2010 | 159 | 0.320 |
Why?
|
Cell Count | 3 | 2020 | 1835 | 0.320 |
Why?
|
Keratitis, Herpetic | 1 | 2009 | 77 | 0.310 |
Why?
|
Ketorolac Tromethamine | 2 | 2006 | 21 | 0.300 |
Why?
|
Mycobacterium chelonae | 1 | 2007 | 12 | 0.290 |
Why?
|
Virus Activation | 1 | 2009 | 322 | 0.280 |
Why?
|
Epithelium, Corneal | 3 | 2023 | 254 | 0.280 |
Why?
|
Scleritis | 1 | 2007 | 96 | 0.280 |
Why?
|
Retrospective Studies | 23 | 2023 | 81834 | 0.270 |
Why?
|
Iatrogenic Disease | 1 | 2009 | 552 | 0.260 |
Why?
|
Prednisolone | 5 | 2009 | 327 | 0.260 |
Why?
|
Wounds, Nonpenetrating | 1 | 2013 | 813 | 0.260 |
Why?
|
Monkeypox virus | 2 | 2023 | 43 | 0.260 |
Why?
|
Developing Countries | 3 | 2015 | 2901 | 0.260 |
Why?
|
Drug Resistance, Bacterial | 3 | 2008 | 1064 | 0.250 |
Why?
|
Protein Kinase Inhibitors | 1 | 2021 | 5709 | 0.240 |
Why?
|
Middle Aged | 33 | 2024 | 223418 | 0.230 |
Why?
|
Reoperation | 4 | 2020 | 4342 | 0.230 |
Why?
|
Optic Nerve Diseases | 1 | 2008 | 342 | 0.230 |
Why?
|
Male | 42 | 2024 | 364781 | 0.220 |
Why?
|
Edetic Acid | 1 | 2024 | 278 | 0.220 |
Why?
|
Herpesvirus 1, Human | 1 | 2009 | 744 | 0.220 |
Why?
|
Eye Infections | 1 | 2004 | 62 | 0.220 |
Why?
|
Capsulorhexis | 1 | 2023 | 12 | 0.220 |
Why?
|
Aqueous Humor | 1 | 2024 | 153 | 0.220 |
Why?
|
Mass Screening | 1 | 2019 | 5455 | 0.210 |
Why?
|
Postoperative Care | 1 | 2010 | 1481 | 0.210 |
Why?
|
Contrast Sensitivity | 1 | 2024 | 253 | 0.200 |
Why?
|
Abnormalities, Multiple | 1 | 2010 | 1424 | 0.200 |
Why?
|
Female | 42 | 2024 | 396943 | 0.200 |
Why?
|
Scleral Diseases | 2 | 2002 | 22 | 0.200 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2006 | 2279 | 0.200 |
Why?
|
Eye Burns | 1 | 2002 | 65 | 0.200 |
Why?
|
Eye Neoplasms | 3 | 2010 | 307 | 0.200 |
Why?
|
Treatment Outcome | 16 | 2024 | 65409 | 0.190 |
Why?
|
Device Removal | 3 | 2012 | 641 | 0.190 |
Why?
|
Prosthesis Design | 4 | 2021 | 2126 | 0.190 |
Why?
|
Polypropylenes | 1 | 2021 | 63 | 0.190 |
Why?
|
Glaucoma Drainage Implants | 1 | 2022 | 107 | 0.180 |
Why?
|
Aged | 19 | 2024 | 171520 | 0.180 |
Why?
|
Microscopy, Confocal | 4 | 2016 | 1977 | 0.180 |
Why?
|
Tonometry, Ocular | 1 | 2021 | 238 | 0.180 |
Why?
|
Keratoconjunctivitis | 2 | 1998 | 42 | 0.180 |
Why?
|
Lacerations | 1 | 2002 | 149 | 0.170 |
Why?
|
Decision Support Techniques | 1 | 2010 | 2010 | 0.170 |
Why?
|
Drug Therapy, Combination | 5 | 2012 | 6320 | 0.170 |
Why?
|
rho-Associated Kinases | 1 | 2021 | 286 | 0.170 |
Why?
|
Rupture, Spontaneous | 2 | 2013 | 365 | 0.160 |
Why?
|
Intraocular Pressure | 3 | 2022 | 1304 | 0.160 |
Why?
|
Adult | 27 | 2023 | 223542 | 0.150 |
Why?
|
Learning Curve | 1 | 2020 | 233 | 0.150 |
Why?
|
Ciliary Body | 2 | 1997 | 168 | 0.150 |
Why?
|
Capsule Opacification | 1 | 2017 | 3 | 0.150 |
Why?
|
Surgical Wound Infection | 1 | 2007 | 1544 | 0.150 |
Why?
|
Models, Theoretical | 1 | 2010 | 3590 | 0.150 |
Why?
|
Adenovirus Infections, Human | 1 | 1998 | 76 | 0.140 |
Why?
|
Anesthesia, Local | 1 | 2000 | 278 | 0.140 |
Why?
|
Eye Infections, Viral | 1 | 1998 | 60 | 0.140 |
Why?
|
Anti-Bacterial Agents | 5 | 2011 | 7471 | 0.140 |
Why?
|
Spectrum Analysis | 1 | 2019 | 450 | 0.140 |
Why?
|
Acute Disease | 2 | 2021 | 7246 | 0.140 |
Why?
|
Health Care Costs | 1 | 2010 | 3265 | 0.140 |
Why?
|
Burns, Chemical | 1 | 2018 | 124 | 0.140 |
Why?
|
Diagnostic Techniques, Ophthalmological | 1 | 2019 | 252 | 0.140 |
Why?
|
Choroid Neoplasms | 1 | 1998 | 177 | 0.140 |
Why?
|
Adjuvants, Pharmaceutic | 1 | 1996 | 48 | 0.130 |
Why?
|
Drug Implants | 1 | 2016 | 231 | 0.130 |
Why?
|
Hot Temperature | 1 | 2002 | 1439 | 0.130 |
Why?
|
Glare | 1 | 2015 | 6 | 0.130 |
Why?
|
Elasticity | 2 | 2015 | 658 | 0.130 |
Why?
|
Cysts | 1 | 2020 | 685 | 0.120 |
Why?
|
Glaucoma, Open-Angle | 2 | 2021 | 742 | 0.120 |
Why?
|
Patient Satisfaction | 2 | 2018 | 3484 | 0.120 |
Why?
|
Wounds, Penetrating | 1 | 1997 | 316 | 0.120 |
Why?
|
Axial Length, Eye | 1 | 2014 | 36 | 0.120 |
Why?
|
Pigmentation | 1 | 2015 | 143 | 0.120 |
Why?
|
Homosexuality, Male | 1 | 2023 | 1345 | 0.120 |
Why?
|
Intravitreal Injections | 1 | 2016 | 401 | 0.120 |
Why?
|
Melanoma, Experimental | 1 | 1998 | 561 | 0.120 |
Why?
|
Antibiotic Prophylaxis | 2 | 2014 | 640 | 0.120 |
Why?
|
Retinal Diseases | 2 | 2018 | 711 | 0.120 |
Why?
|
Air | 2 | 2013 | 187 | 0.110 |
Why?
|
Follow-Up Studies | 8 | 2022 | 39430 | 0.110 |
Why?
|
Bioartificial Organs | 1 | 2014 | 47 | 0.110 |
Why?
|
Collagen | 2 | 2013 | 2646 | 0.110 |
Why?
|
Vitrectomy | 1 | 2016 | 392 | 0.110 |
Why?
|
Cogan Syndrome | 1 | 2013 | 10 | 0.110 |
Why?
|
Crystallins | 1 | 1993 | 75 | 0.110 |
Why?
|
Disease Outbreaks | 1 | 2023 | 1764 | 0.110 |
Why?
|
Endotamponade | 1 | 2013 | 37 | 0.110 |
Why?
|
Apraxias | 1 | 2013 | 58 | 0.100 |
Why?
|
Blepharitis | 2 | 2005 | 35 | 0.100 |
Why?
|
Silicone Elastomers | 1 | 2012 | 78 | 0.100 |
Why?
|
Trichosporon | 1 | 2012 | 9 | 0.100 |
Why?
|
Corneal Endothelial Cell Loss | 1 | 2012 | 24 | 0.100 |
Why?
|
Lacrimal Apparatus | 1 | 2014 | 223 | 0.100 |
Why?
|
Lupus Erythematosus, Discoid | 2 | 2005 | 61 | 0.100 |
Why?
|
Aza Compounds | 1 | 2011 | 34 | 0.100 |
Why?
|
Intraoperative Period | 1 | 2012 | 513 | 0.090 |
Why?
|
Standard of Care | 1 | 2016 | 571 | 0.090 |
Why?
|
Ophthalmologic Surgical Procedures | 2 | 2007 | 354 | 0.090 |
Why?
|
Conjunctivitis | 2 | 2005 | 156 | 0.090 |
Why?
|
Wound Healing | 1 | 2002 | 2819 | 0.090 |
Why?
|
Refractive Errors | 1 | 2013 | 148 | 0.090 |
Why?
|
Biometry | 1 | 2014 | 565 | 0.090 |
Why?
|
Tissue Donors | 1 | 2021 | 2377 | 0.090 |
Why?
|
Cross-Linking Reagents | 2 | 2013 | 692 | 0.090 |
Why?
|
Microbial Sensitivity Tests | 3 | 2008 | 1965 | 0.090 |
Why?
|
Aspergillus fumigatus | 1 | 2012 | 158 | 0.090 |
Why?
|
Immunoenzyme Techniques | 2 | 2010 | 1706 | 0.090 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2016 | 776 | 0.090 |
Why?
|
Pilot Projects | 2 | 2021 | 8730 | 0.090 |
Why?
|
Diagnostic Tests, Routine | 1 | 2016 | 792 | 0.090 |
Why?
|
Sudan | 1 | 2010 | 86 | 0.090 |
Why?
|
Polymethyl Methacrylate | 1 | 2011 | 132 | 0.090 |
Why?
|
Stromal Cells | 1 | 2016 | 1335 | 0.090 |
Why?
|
Program Development | 1 | 2016 | 1296 | 0.090 |
Why?
|
Retinoblastoma | 1 | 1993 | 321 | 0.090 |
Why?
|
Microscopy | 2 | 2020 | 909 | 0.090 |
Why?
|
Glucocorticoids | 3 | 2009 | 2170 | 0.090 |
Why?
|
Neurilemmoma | 1 | 1995 | 524 | 0.080 |
Why?
|
Epithelial Cells | 1 | 2002 | 3697 | 0.080 |
Why?
|
Goldenhar Syndrome | 1 | 2010 | 40 | 0.080 |
Why?
|
Curriculum | 1 | 2023 | 3778 | 0.080 |
Why?
|
Antifungal Agents | 2 | 2012 | 761 | 0.080 |
Why?
|
Vimentin | 1 | 2010 | 257 | 0.080 |
Why?
|
Anti-Inflammatory Agents | 3 | 2018 | 1816 | 0.080 |
Why?
|
Elasticity Imaging Techniques | 1 | 2014 | 391 | 0.080 |
Why?
|
Retina | 2 | 2018 | 2663 | 0.080 |
Why?
|
Visually Impaired Persons | 1 | 2010 | 79 | 0.080 |
Why?
|
Autoimmune Diseases | 1 | 2021 | 2260 | 0.080 |
Why?
|
Dermoid Cyst | 1 | 2010 | 92 | 0.080 |
Why?
|
Sickness Impact Profile | 1 | 2010 | 299 | 0.080 |
Why?
|
Finland | 1 | 2010 | 609 | 0.080 |
Why?
|
Mycoses | 2 | 2007 | 386 | 0.080 |
Why?
|
Aged, 80 and over | 6 | 2024 | 59680 | 0.080 |
Why?
|
Keratins | 1 | 2010 | 502 | 0.080 |
Why?
|
Acyclovir | 1 | 2009 | 267 | 0.080 |
Why?
|
Titanium | 1 | 2011 | 495 | 0.080 |
Why?
|
Surgical Flaps | 2 | 2007 | 1683 | 0.080 |
Why?
|
Ethiopia | 1 | 2010 | 481 | 0.080 |
Why?
|
Benzamidines | 1 | 2007 | 20 | 0.070 |
Why?
|
Chloramphenicol | 1 | 2007 | 67 | 0.070 |
Why?
|
Biguanides | 1 | 2007 | 21 | 0.070 |
Why?
|
Graft Rejection | 1 | 2021 | 4505 | 0.070 |
Why?
|
Education, Medical, Graduate | 1 | 2020 | 2411 | 0.070 |
Why?
|
Alternaria | 1 | 2007 | 42 | 0.070 |
Why?
|
Postoperative Period | 1 | 2012 | 1833 | 0.070 |
Why?
|
Aniridia | 1 | 2007 | 36 | 0.070 |
Why?
|
Eyelids | 1 | 2010 | 280 | 0.070 |
Why?
|
Corneal Neovascularization | 1 | 2009 | 185 | 0.070 |
Why?
|
Clarithromycin | 1 | 2007 | 87 | 0.070 |
Why?
|
Patient Selection | 1 | 2019 | 4266 | 0.070 |
Why?
|
Papilledema | 1 | 2008 | 130 | 0.070 |
Why?
|
Models, Economic | 1 | 2010 | 717 | 0.070 |
Why?
|
Quinolines | 1 | 2011 | 769 | 0.060 |
Why?
|
Photosensitizing Agents | 1 | 2010 | 633 | 0.060 |
Why?
|
Disease Management | 1 | 2016 | 2533 | 0.060 |
Why?
|
Body Weights and Measures | 1 | 2006 | 208 | 0.060 |
Why?
|
India | 1 | 2012 | 2323 | 0.060 |
Why?
|
Ultraviolet Rays | 1 | 2010 | 1100 | 0.060 |
Why?
|
Transplantation, Autologous | 1 | 2010 | 2126 | 0.060 |
Why?
|
Costs and Cost Analysis | 1 | 2010 | 1670 | 0.060 |
Why?
|
Prospective Studies | 4 | 2021 | 54914 | 0.060 |
Why?
|
Photochemotherapy | 1 | 2010 | 832 | 0.060 |
Why?
|
Syndrome | 1 | 2010 | 3278 | 0.060 |
Why?
|
Quality-Adjusted Life Years | 1 | 2010 | 1734 | 0.050 |
Why?
|
Electrocoagulation | 1 | 2004 | 153 | 0.050 |
Why?
|
Health Care Surveys | 1 | 2010 | 2437 | 0.050 |
Why?
|
Isoindoles | 1 | 2022 | 37 | 0.050 |
Why?
|
Chelating Agents | 1 | 2024 | 385 | 0.050 |
Why?
|
Disease Models, Animal | 3 | 2013 | 18388 | 0.050 |
Why?
|
Trifluridine | 1 | 2022 | 28 | 0.050 |
Why?
|
Health Services Research | 1 | 2010 | 1815 | 0.050 |
Why?
|
Antiviral Agents | 2 | 2009 | 3063 | 0.050 |
Why?
|
Adolescent | 6 | 2016 | 89168 | 0.050 |
Why?
|
Down Syndrome | 1 | 2010 | 914 | 0.050 |
Why?
|
Activities of Daily Living | 1 | 2010 | 2433 | 0.050 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2016 | 5342 | 0.040 |
Why?
|
Retrobulbar Hemorrhage | 1 | 2000 | 10 | 0.040 |
Why?
|
Eye Injuries, Penetrating | 1 | 2002 | 122 | 0.040 |
Why?
|
Anti-Infective Agents | 1 | 2007 | 987 | 0.040 |
Why?
|
Child, Preschool | 5 | 2010 | 42623 | 0.040 |
Why?
|
Aging | 2 | 2016 | 8761 | 0.040 |
Why?
|
Disease Progression | 2 | 2014 | 13655 | 0.040 |
Why?
|
Stress, Mechanical | 2 | 2016 | 1680 | 0.040 |
Why?
|
Angiogenesis Inhibitors | 1 | 2009 | 2062 | 0.040 |
Why?
|
Fundus Oculi | 2 | 1998 | 560 | 0.040 |
Why?
|
Optic Nerve Injuries | 1 | 2000 | 150 | 0.040 |
Why?
|
Prognosis | 3 | 2007 | 30028 | 0.040 |
Why?
|
Sclerostomy | 1 | 1998 | 16 | 0.040 |
Why?
|
Ultrasonography | 2 | 2006 | 5995 | 0.040 |
Why?
|
Combined Modality Therapy | 2 | 2007 | 8559 | 0.040 |
Why?
|
Tromethamine | 1 | 1997 | 31 | 0.040 |
Why?
|
Tolmetin | 1 | 1997 | 24 | 0.040 |
Why?
|
Tumor Cells, Cultured | 2 | 1998 | 6135 | 0.040 |
Why?
|
Child | 6 | 2020 | 80863 | 0.040 |
Why?
|
Carbonic Anhydrase Inhibitors | 1 | 2018 | 91 | 0.040 |
Why?
|
Occlusive Dressings | 1 | 1997 | 52 | 0.040 |
Why?
|
Benzamides | 1 | 2023 | 1381 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2010 | 5532 | 0.040 |
Why?
|
Double-Blind Method | 2 | 2024 | 12450 | 0.030 |
Why?
|
Injections | 1 | 2000 | 840 | 0.030 |
Why?
|
Laser Therapy | 1 | 2004 | 1107 | 0.030 |
Why?
|
Amyloid beta-Peptides | 1 | 2010 | 3891 | 0.030 |
Why?
|
Ultrasonography, Doppler, Color | 1 | 1998 | 235 | 0.030 |
Why?
|
Orbit | 1 | 2000 | 459 | 0.030 |
Why?
|
Risk Factors | 3 | 2022 | 74915 | 0.030 |
Why?
|
History, 20th Century | 1 | 2004 | 2772 | 0.030 |
Why?
|
ROC Curve | 1 | 2023 | 3624 | 0.030 |
Why?
|
Oculomotor Muscles | 1 | 2000 | 405 | 0.030 |
Why?
|
Phlebitis | 1 | 1995 | 35 | 0.030 |
Why?
|
Retinal Vein | 1 | 1995 | 47 | 0.030 |
Why?
|
Incidence | 4 | 2022 | 21552 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 3 | 2014 | 4077 | 0.030 |
Why?
|
Central Nervous System Diseases | 1 | 2000 | 521 | 0.030 |
Why?
|
Gonioscopy | 1 | 1995 | 157 | 0.030 |
Why?
|
Tissue Culture Techniques | 1 | 2016 | 290 | 0.030 |
Why?
|
Fluorescein Angiography | 2 | 1998 | 1086 | 0.030 |
Why?
|
United States | 4 | 2022 | 73121 | 0.030 |
Why?
|
Rabbits | 2 | 1998 | 4786 | 0.030 |
Why?
|
Pressure | 1 | 1997 | 1173 | 0.030 |
Why?
|
Paraneoplastic Syndromes | 1 | 1995 | 155 | 0.030 |
Why?
|
Administration, Topical | 2 | 2009 | 707 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2006 | 10784 | 0.030 |
Why?
|
Infant | 4 | 2010 | 36497 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2016 | 13708 | 0.030 |
Why?
|
Anesthetics, Local | 1 | 2000 | 1005 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2009 | 9263 | 0.020 |
Why?
|
Pigmentation Disorders | 1 | 1992 | 104 | 0.020 |
Why?
|
Microscopy, Electron | 1 | 1995 | 2565 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2009 | 15965 | 0.020 |
Why?
|
Macaca | 1 | 1993 | 417 | 0.020 |
Why?
|
Blotting, Northern | 1 | 1993 | 1553 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2016 | 13589 | 0.020 |
Why?
|
Neuroprotective Agents | 1 | 2018 | 960 | 0.020 |
Why?
|
Animals | 8 | 2016 | 169418 | 0.020 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2016 | 757 | 0.020 |
Why?
|
Fibrosis | 1 | 1998 | 2076 | 0.020 |
Why?
|
Demography | 1 | 2015 | 1643 | 0.020 |
Why?
|
Riboflavin | 1 | 2010 | 107 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 1998 | 3637 | 0.020 |
Why?
|
Protein Structure, Quaternary | 1 | 2010 | 429 | 0.020 |
Why?
|
China | 1 | 2015 | 2398 | 0.020 |
Why?
|
Epinephrine | 1 | 1992 | 795 | 0.020 |
Why?
|
Steroids | 1 | 1994 | 937 | 0.020 |
Why?
|
Alzheimer Disease | 1 | 2010 | 8721 | 0.020 |
Why?
|
Scattering, Radiation | 1 | 2010 | 491 | 0.020 |
Why?
|
Hydroxychloroquine | 2 | 2005 | 427 | 0.020 |
Why?
|
Polymyxin B | 1 | 2007 | 44 | 0.020 |
Why?
|
Trimethoprim | 1 | 2007 | 80 | 0.020 |
Why?
|
Ofloxacin | 1 | 2007 | 66 | 0.020 |
Why?
|
Itraconazole | 1 | 2007 | 43 | 0.020 |
Why?
|
Cefazolin | 1 | 2008 | 95 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2016 | 3619 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2005 | 7451 | 0.020 |
Why?
|
Amphotericin B | 1 | 2007 | 143 | 0.020 |
Why?
|
Biopsy | 2 | 1999 | 6816 | 0.020 |
Why?
|
Gentamicins | 1 | 2008 | 245 | 0.020 |
Why?
|
Eye Proteins | 1 | 2010 | 633 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2018 | 4362 | 0.020 |
Why?
|
Ciprofloxacin | 1 | 2008 | 313 | 0.020 |
Why?
|
Cattle | 1 | 2012 | 3830 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2023 | 22293 | 0.020 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2008 | 342 | 0.020 |
Why?
|
Debridement | 1 | 2007 | 494 | 0.010 |
Why?
|
Prevalence | 1 | 2021 | 15880 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2013 | 20231 | 0.010 |
Why?
|
Light | 1 | 2010 | 1357 | 0.010 |
Why?
|
Radiography | 1 | 1995 | 6995 | 0.010 |
Why?
|
Brain | 1 | 2010 | 27438 | 0.010 |
Why?
|
Swine | 1 | 2013 | 5996 | 0.010 |
Why?
|
Cytokines | 1 | 2018 | 7449 | 0.010 |
Why?
|
Tumor Microenvironment | 1 | 2016 | 3939 | 0.010 |
Why?
|
Time Factors | 4 | 2011 | 40271 | 0.010 |
Why?
|
Pain | 1 | 1997 | 5096 | 0.010 |
Why?
|
Young Adult | 3 | 2016 | 60045 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2015 | 12096 | 0.010 |
Why?
|
Bone Marrow Transplantation | 1 | 1989 | 2702 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2010 | 4834 | 0.010 |
Why?
|
Drug Combinations | 1 | 2007 | 2079 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2016 | 11249 | 0.010 |
Why?
|
Electroretinography | 2 | 1995 | 524 | 0.010 |
Why?
|
Logistic Models | 1 | 2015 | 13324 | 0.010 |
Why?
|
Rupture | 1 | 2002 | 444 | 0.010 |
Why?
|
Gene Expression | 1 | 1993 | 7605 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 26351 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 1998 | 22365 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 1997 | 36840 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2010 | 13452 | 0.010 |
Why?
|
Mice | 2 | 1998 | 82045 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2009 | 3520 | 0.010 |
Why?
|
RNA, Messenger | 1 | 1993 | 12813 | 0.010 |
Why?
|
Phenotype | 1 | 2016 | 16712 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2010 | 17647 | 0.010 |
Why?
|
Chronic Disease | 2 | 2005 | 9382 | 0.010 |
Why?
|
Hypertrophy | 1 | 1999 | 562 | 0.010 |
Why?
|
Melanoma | 1 | 1995 | 5740 | 0.010 |
Why?
|
Radioisotopes | 1 | 1997 | 516 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 1995 | 5891 | 0.010 |
Why?
|
Antirheumatic Agents | 1 | 2005 | 1374 | 0.010 |
Why?
|
Night Blindness | 1 | 1995 | 56 | 0.010 |
Why?
|
Diagnosis, Differential | 2 | 2005 | 13026 | 0.010 |
Why?
|
Forecasting | 1 | 2004 | 2950 | 0.010 |
Why?
|
Retinal Rod Photoreceptor Cells | 1 | 1995 | 204 | 0.010 |
Why?
|
Uveal Diseases | 1 | 1992 | 45 | 0.010 |
Why?
|
Prolapse | 1 | 1992 | 63 | 0.010 |
Why?
|
Gadolinium | 1 | 1997 | 965 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2004 | 8051 | 0.000 |
Why?
|
Image Enhancement | 1 | 1997 | 2894 | 0.000 |
Why?
|
Optic Nerve | 1 | 1989 | 572 | 0.000 |
Why?
|
Edema | 1 | 1989 | 766 | 0.000 |
Why?
|